DE68918556D1 - Bindeproteine für insulinähnliche Wachstumsfaktoren. - Google Patents

Bindeproteine für insulinähnliche Wachstumsfaktoren.

Info

Publication number
DE68918556D1
DE68918556D1 DE68918556T DE68918556T DE68918556D1 DE 68918556 D1 DE68918556 D1 DE 68918556D1 DE 68918556 T DE68918556 T DE 68918556T DE 68918556 T DE68918556 T DE 68918556T DE 68918556 D1 DE68918556 D1 DE 68918556D1
Authority
DE
Germany
Prior art keywords
insulin
growth factors
binding proteins
somatomedins
bind
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68918556T
Other languages
English (en)
Inventor
Christopher Binkert
Guenther Heinrich
Juerg Schwander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Sandoz Patent GmbH
Original Assignee
Sandoz AG
Sandoz Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG, Sandoz Patent GmbH filed Critical Sandoz AG
Application granted granted Critical
Publication of DE68918556D1 publication Critical patent/DE68918556D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743Insulin-like growth factor binding protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE68918556T 1988-11-11 1989-11-08 Bindeproteine für insulinähnliche Wachstumsfaktoren. Expired - Lifetime DE68918556D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888826451A GB8826451D0 (en) 1988-11-11 1988-11-11 Improvements in/relating to organic compounds

Publications (1)

Publication Number Publication Date
DE68918556D1 true DE68918556D1 (de) 1994-11-03

Family

ID=10646720

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68918556T Expired - Lifetime DE68918556D1 (de) 1988-11-11 1989-11-08 Bindeproteine für insulinähnliche Wachstumsfaktoren.

Country Status (16)

Country Link
EP (1) EP0369943B1 (de)
JP (1) JPH0341096A (de)
AT (1) ATE112311T1 (de)
AU (1) AU623447B2 (de)
CA (1) CA2002609A1 (de)
DE (1) DE68918556D1 (de)
DK (1) DK564989A (de)
FI (1) FI895346A0 (de)
GB (1) GB8826451D0 (de)
HU (2) HU895607D0 (de)
IL (1) IL92257A0 (de)
MY (1) MY104673A (de)
NZ (1) NZ231333A (de)
PL (1) PL162290B1 (de)
PT (1) PT92278B (de)
ZA (1) ZA898610B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
WO1992003152A1 (en) * 1990-08-28 1992-03-05 Chiron Corporation New insulin-like growth factor binding protein (igfbp-4)
US5212074A (en) * 1990-08-28 1993-05-18 Chiron Corporation Genetic material encoding new insulin-like growth factor binding protein igfbp-6
PT98806B (pt) * 1990-08-28 1999-01-29 Chiron Corp Processo de preparacao de uma molecula de dna, um microorganismo ou linha celular recombinantes, e de producao da igfbp-4 ou um seu fragmento
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US6326154B1 (en) 1990-11-19 2001-12-04 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
CA2100083A1 (en) 1991-01-08 1992-07-09 Michael C. Kiefer Insulin-like growth factor binding protein
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
AU6626794A (en) * 1993-04-07 1994-10-24 Amgen Boulder Inc. Methods of using insulin-like growth factor binding proteins
DE69431631T2 (de) * 1993-09-20 2003-07-31 Celtrix Pharma Behandlung von hematologischen störungen mit einem igf-1/igfbp-3 komplex
SE9303784D0 (sv) * 1993-11-16 1993-11-16 Kabi Pharmacia Ab Igf
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
IL143834A0 (en) 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
JP3971108B2 (ja) 1999-01-06 2007-09-05 ジェネンテック・インコーポレーテッド インシュリン様成長因子(igf)i突然変異体
ES2301547T3 (es) 2000-05-16 2008-07-01 Genentech, Inc. Tratamiento de trastornos del cartilago.
IL157705A0 (en) 2001-03-14 2004-03-28 Genentech Inc Igf antagonist peptides
ES2527871T3 (es) 2003-05-01 2015-02-02 Imclone Llc Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
WO2005049792A2 (en) 2003-09-12 2005-06-02 Tercica, Inc. Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency
AU2004278311A1 (en) 2003-10-03 2005-04-14 Genentech, Inc. IGF binding proteins
DK2100614T3 (da) 2005-06-17 2013-10-28 Imclone Llc Antistof mod PDGFR-alfa til anvendelse ved behandlingen af tumorer
AP2008004569A0 (en) 2006-02-03 2008-08-31 Imclone Systems Inc IGR-IR antagonists as adjuvants for treatment of prostrate cancer
BR112020004760A2 (pt) 2017-09-11 2020-09-15 Shire Human Genetic Therapies, Inc métodos e composições para tratamento de doenças pulmonares crônicas
KR20230113287A (ko) 2020-10-19 2023-07-28 오크 힐 바이오 리미티드 신생아에 사용하기에 적합한 조성물
WO2023139115A1 (en) 2022-01-19 2023-07-27 Oak Hill Bio Limited Compositions and methods for reducing oxidation of igf‐1/igfbp
WO2023242442A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Method of maturing/differentiating neurons and/or modulating the vagus nerve
WO2023242440A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants
WO2023242439A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Vascular stabilisation (preterm infants)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK131988A (da) * 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
AU1955388A (en) * 1988-04-12 1989-11-03 Synergen, Inc. Method for potentiating and inhibiting insulin-like growth factor activity

Also Published As

Publication number Publication date
PL162290B1 (pl) 1993-09-30
EP0369943B1 (de) 1994-09-28
EP0369943A1 (de) 1990-05-23
DK564989A (da) 1990-05-12
IL92257A0 (en) 1990-07-26
ATE112311T1 (de) 1994-10-15
PT92278A (pt) 1990-05-31
ZA898610B (en) 1991-07-31
AU4453689A (en) 1990-06-07
FI895346A0 (fi) 1989-11-09
NZ231333A (en) 1992-10-28
MY104673A (en) 1994-05-31
CA2002609A1 (en) 1990-05-11
PT92278B (pt) 1995-09-12
JPH0341096A (ja) 1991-02-21
DK564989D0 (da) 1989-11-10
HU895607D0 (en) 1990-01-28
HUT53936A (en) 1990-12-28
AU623447B2 (en) 1992-05-14
GB8826451D0 (en) 1988-12-14
HU895836D0 (en) 1990-01-28

Similar Documents

Publication Publication Date Title
DE68918556D1 (de) Bindeproteine für insulinähnliche Wachstumsfaktoren.
DE69021263T2 (de) Fibronektinbindungsprotein und dessen Herstellung.
ES2155819T3 (es) Inmunoglobulinas hibridas.
ZA882407B (en) Human somatomedin carrier protein subunits and process for producing them
HK1000826A1 (en) Recombinant dna molecules hosts processes and human somatomedin carrier protein-like polypeptides
DE3853446D1 (de) Fibronectinbindungsprotein und dessen Herstellung.
DE59310280D1 (de) Verfahren zur Herstellung von Konjugaten aus einem spezifischen Bindungspartner und einem kohlenhydrathaltigen Protein
EP0603672A3 (de) Verfahren zur Herstellung von rekombinanten und synthetischen Peptiden und deren Verwendung.

Legal Events

Date Code Title Description
8332 No legal effect for de